Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0T5PO
|
|||
| Former ID |
DNC003593
|
|||
| Drug Name |
ROLIPRAM
|
|||
| Synonyms |
61413-54-5; ZK 62711; Rolipramum; Rolipramum [Latin]; 4-[3-(Cyclopentyloxy)-4-methoxyphenyl]-2-pyrrolidinone; Adeo; Rolipram [USAN:INN]; 4-[3-(cyclopentyloxy)-4-methoxyphenyl]pyrrolidin-2-one; 4-(3-(cyclopentyloxy)-4-methoxyphenyl)pyrrolidin-2-one; 4-(3-(Cyclopentyloxy)-4-methoxyphenyl)-2-pyrrolidinone; (R,S)-rolipram; ZK-62711; CHEMBL63; EINECS 262-771-1; BRN 1588548; MLS000069691; CHEBI:104872; HJORMJIFDVBMOB-UHFFFAOYSA-N; 4-(3-Cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone; [3H]rolipram
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C16H21NO3
|
|||
| Canonical SMILES |
COC1=C(C=C(C=C1)C2CC(=O)NC2)OC3CCCC3
|
|||
| InChI |
1S/C16H21NO3/c1-19-14-7-6-11(12-9-16(18)17-10-12)8-15(14)20-13-4-2-3-5-13/h6-8,12-13H,2-5,9-10H2,1H3,(H,17,18)
|
|||
| InChIKey |
HJORMJIFDVBMOB-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 61413-54-5
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
611179, 841134, 855869, 3153149, 5146349, 7848845, 7980298, 8153132, 11121421, 11121901, 11362490, 11365052, 11367614, 11370251, 11370252, 11373215, 11375776, 11466952, 11468072, 11486743, 12013590, 15222043, 17405628, 22391521, 24278196, 26681488, 26719663, 26719664, 26752319, 26752320, 26752321, 26759453, 29224160, 46386779, 46386848, 46487946, 46514702, 47217030, 47365441, 47440514, 47811011, 48035380, 48185221, 48334758, 49635712, 49699213, 50039658, 50105263, 50105264, 50105265
|
|||
| ChEBI ID |
CHEBI:104872
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Phosphodiesterase 4A (PDE4A) | Target Info | Inhibitor | [2] |
| Phosphodiesterase 4B (PDE4B) | Target Info | Inhibitor | [3] | |
| Phosphodiesterase 4D (PDE4D) | Target Info | Inhibitor | [4] | |
| Phosphodiesterase 5A (PDE5A) | Target Info | Inhibitor | [5] | |
| KEGG Pathway | Purine metabolism | |||
| cAMP signaling pathway | ||||
| Morphine addiction | ||||
| cGMP-PKG signaling pathway | ||||
| NetPath Pathway | IL5 Signaling Pathway | |||
| IL2 Signaling Pathway | ||||
| TGF_beta_Receptor Signaling Pathway | ||||
| Pathwhiz Pathway | Purine Metabolism | |||
| Reactome | DARPP-32 events | |||
| G alpha (s) signalling events | ||||
| cGMP effects | ||||
| WikiPathways | G Protein Signaling Pathways | |||
| Myometrial Relaxation and Contraction Pathways | ||||
| Nuclear Receptors Meta-Pathway | ||||
| Opioid Signalling | ||||
| TSH signaling pathway | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5313). | |||
| REF 2 | Discovery of micromolar PDE IV inhibitors that exhibit much reduced affinity for the [3H]rolipram binding site: 3-norbornyloxy-4-methoxyphenylmethylene oxindoles, Bioorg. Med. Chem. Lett. 5(17):1965-1968 (1995). | |||
| REF 3 | Novel heterocyclic-fused pyridazinones as potent and selective phosphodiesterase IV inhibitors. J Med Chem. 1997 May 9;40(10):1417-21. | |||
| REF 4 | In silico search for multi-target anti-inflammatories in Chinese herbs and formulas. Bioorg Med Chem. 2010 Mar 15;18(6):2204-2218. | |||
| REF 5 | Cyclic GMP phosphodiesterase inhibitors. 2. Requirement of 6-substitution of quinazoline derivatives for potent and selective inhibitory activity. J Med Chem. 1994 Jun 24;37(13):2106-11. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.